MedTrace Logo

Treating Refractory Schizophrenia With rTMS

NCT02242578 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-04-12

Study results available
· View outcomes & findings →

Summary

Symptomatic treatment of the negative symptoms in schizophrenia (such as social withdrawal, affective flattening, poor motivation, and apathy) with medications and psychotherapy are almost non-existent, whereas treatment of the positive symptoms (hallucinations and delusions) has been more effective with psychotropic medications. The proposed research on human subjects using a non-invasive technology (such as repetitive transcranial magnetic stimulation \[rTMS\]) will provide efficacy data for treating negative symptoms.

The hypotheses are that 1) Cerebellar stimulation will cause activation of thalamic and frontal cortical networks associated with attentional processes as a component of the "distracted" affect of schizophrenia; 2) Cerebellar stimulation will cause activation of the reticular activating system (RAS), and this will allow the "mutism", which is a negative symptom, to be partially improved.

Conditions

Interventions

DEVICE

1 Hz rTMS

About 1,000 stimulation pulses over 20 min

DEVICE

10 Hz rTMS

About 1,000 stimulation pulses over 20 min

Sponsors & Collaborators

  • Abbott Medical Devices

    collaborator INDUSTRY

  • University of Texas at Austin

    collaborator OTHER

  • Seton Healthcare Family

    lead OTHER

Principal Investigators

  • Robert Buchanan, MD · Seton Family Hopsitals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-24
Primary Completion
2018-06-11
Completion
2018-06-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02242578 on ClinicalTrials.gov